CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...
Sponsored Content by GBS-CIDP Foundation Intl. Rare disorders are often hard to diagnose, treat and cure. That is why education and research are so important. Such is the case for Guillain Barre or ...
Please provide your email address to receive an email when new articles are posted on . Reasons for misdiagnosis or delayed diagnosis for CIDP are complex and include multiple factors. The FDA ...
The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...
Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth ...
The seventh national conference organised by the Guillain-Barré Syndrome Support Group of New Zealand will be held from 8 to 10 May 2015 at the Sudima Hotel in Rotorua. Guillain-Barré Syndrome (GBS) ...
Dear Dr. Roach: Eight years ago, I was diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy). After several tests, it finally was diagnosed by a spinal tap. One of the effects of ...
CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International is commemorating Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy Awareness Month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback